Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.0063|
|52 Week High||UK£0.006|
|52 Week Low||UK£0.016|
|1 Month Change||1.63%|
|3 Month Change||-34.21%|
|1 Year Change||-39.02%|
|3 Year Change||-65.28%|
|5 Year Change||-61.54%|
|Change since IPO||-97.28%|
Recent News & Updates
|FDBK||GB Healthcare Services||GB Market|
Return vs Industry: FDBK underperformed the UK Healthcare Services industry which returned 45.7% over the past year.
Return vs Market: FDBK underperformed the UK Market which returned 23.4% over the past year.
Stable Share Price: FDBK is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: FDBK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a software tool, which extracts and quantifies texture features in radiological images, assisting research into all tumor types, as well as uncovers biomarkers in medical images; and TexRAD Lung for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, which combines secure instant messaging with the ability to see clinical grade medical images, including X-rays, and CT and MRI scans using portable devices, such as smartphones or tablets.
Feedback Fundamentals Summary
|FDBK fundamental statistics|
Is FDBK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FDBK income statement (TTM)|
|Cost of Revenue||-UK£1.13k|
Last Reported Earnings
Nov 30, 2020
Next Earnings Date
|Earnings per share (EPS)||-0.0011|
|Net Profit Margin||-348.99%|
How did FDBK perform over the long term?See historical performance and comparison
Is Feedback undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FDBK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FDBK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FDBK is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.
PE vs Market: FDBK is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FDBK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FDBK is good value based on its PB Ratio (1.1x) compared to the GB Healthcare Services industry average (6.7x).
How is Feedback forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if FDBK's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if FDBK's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: FDBK's revenue (33.6% per year) is forecast to grow faster than the UK market (5.4% per year).
High Growth Revenue: FDBK's revenue (33.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FDBK's Return on Equity is forecast to be high in 3 years time
How has Feedback performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FDBK is currently unprofitable.
Growing Profit Margin: FDBK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FDBK is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.
Accelerating Growth: Unable to compare FDBK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FDBK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (24.9%).
Return on Equity
High ROE: FDBK has a negative Return on Equity (-20.12%), as it is currently unprofitable.
How is Feedback's financial position?
Financial Position Analysis
Short Term Liabilities: FDBK's short term assets (£4.4M) exceed its short term liabilities (£395.0K).
Long Term Liabilities: FDBK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FDBK is debt free.
Reducing Debt: FDBK has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if FDBK has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FDBK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Feedback current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FDBK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FDBK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FDBK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FDBK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FDBK's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tom Oakley (33 yo)
Dr. Thomas James Oakley, also known as Tom,BM(Hons) BSc (Hons), has been Chief Executive Officer of Feedback plc since April 9, 2019 and Director since October 2019. Dr Oakley has been Chief Executive Offi...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD232.39K) is about average for companies of similar size in the UK market ($USD323.29K).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
Experienced Board: FDBK's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Feedback plc's employee growth, exchange listings and data sources
- Name: Feedback plc
- Ticker: FDBK
- Exchange: AIM
- Founded: 1958
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£6.668m
- Shares outstanding: 1.07b
- Website: https://fbkmed.com/feedback-plc
Number of Employees
- Feedback plc
- Health Foundry
- Canterbury House
- Greater London
- SE1 7LL
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 17:46|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.